10 The loss of the tumor suppressor gene CDKN2A is a frequent occurrence that, for example, contributes to melanoma progression. 10 Consequently, therapeutic strategies targeting and reconstituting CDKN2A loss hold considerable promise for enhancing melanoma treatment outcomes. 10 A notable example of such a strategy involves the pharmacological inhibition of p16, which targets CDK4/6. 10. Here, CDK4 is linked to melanoma.